The potential relationship between QTc interval prolongation and ziprasidone treatment: Three cases

Journal of Psychopharmacology

Volumn 23, Issue 8, 2009, Pages 993-996

  Eker, S S ^a   Sarandol, A ^a   Akkaya, C ^a   Sivrioglu, E Y ^a   Kirli, S ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Antipsychotic; QTc prolongation; Ziprasidone

Indexed keywords

AMISULPRIDE; BIPERIDEN; BORNAPRINE; GLIMEPIRIDE; HALOPERIDOL; LITHIUM; METFORMIN; QUETIAPINE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; THIAZOLES;

EID: 70449419969     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108093843     Document Type: Article

References (37)

1. Allison, DB, Mentore, JL, Heo, M., Chandler, LP, Cappelleri, JC, Infante, MC, et al. (1999) Antipsychotic- induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
2. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, fourth ed. Washington, DC ; American Psychiatric Association.
3. Arato, M., OConnor, R., Meltzer, HY ; on behalf of ZEUS Study group (2002) A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17: 207-215.
4. Beedham, C., Miceli, JJ, Obach, RS (2003) Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23: 229-232.
5. Coulouvrat, C., Dondey-Nouvel, L. (1999) Safety of amisulpride (Solian). a review of 11 clinical studies. Int Clin Psychopharmacol 14: 209-218.
6. Czekalla, J., Kollack-Walker, S., Beasley, C. (2001) Cardiac safety of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 62 (Suppl. 2). 35-40.
7. Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20: 491-505.
8. FDA (2000) Psychopharmacological drugs advisory committee. Briefing information for Zeldox (ziprasidone hydrochloride capsules) 19 July. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1b.pdf (accessed 19.02.08).
9. Fritze, J., Bandelow, B. (1998) The QT interval and atypical antipsychotic, sertindole. Int J Psychiatry Clin Pract 2: 265-273.
10. Fulop, G., Phillips, RA, Shapiro, AK, Gomes, JA, Shapiro, E., Nordlie, JW (1987) ECG changes during haloperidol and pimozide treatment of Tourettes disorder. Am J Psychiatry 144: 673-675.
11. Gajwani, P., Pozuelo, L., Tesar, GE (2000) QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 41: 63-65.
12. Glassmann, AH, Bigger, JT (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158: 1774-1782.
13. Haddad, PM, Anderson, IM (2002) Antipsychotic-related QTc prolongation, torsades de pointes and sudden death. Drugs 62: 1649-1671.
14. Hale, AS (1998) A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 13 (Suppl. 3). 65-70.
15. Haverkamp, W., Breithardt, G., Camm, AJ, Janse, MJ, Rosen, MR, Antzelevitch, C., et al. (2000) The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Eur Heart J 21: 1216-1231.
16. Kane, JM, Khanna, S., Rajadhyaksha, S., Giller, E. (2006) Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 21: 21-28.
17. Kasper, S., Lerman, MN, McQuade, RD, Saha, A., Carson, WH, Ali, M., et al. (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6: 325-337.
18. Keck, P., Buffenstein, A., Ferguson, J., Feighner, J., Jaffe, W., Harrigan, EP, et al. (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 140: 173-184.
19. Kelly, HG, Fay, JE, Laverty, SG (1963) Thioridazine hydrochloride (Mellaril). its effects on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 89: 546-554.
20. Kelly, DL, Love, RC (2001) Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol Bull 35: 66-79.
21. Kriwisky, M., Perry, GY, Tarchitsky, D., Gutman, Y., Kishon, Y. (1990) Haloperidol-induced torsades de pointes. Chest 98: 482-484.
22. Kudla, D., Lambert, M., Domin, S., Kasper, S., Naber, D. (2007) Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry 22: 195-202.
23. Langtry, HD, Balfour, JA (1998) Glimepiride: a review of its use in the management of type 2 diabetes mellitus. Drugs 55: 563-584.
24. Levy, WO, Robichaux-Keene, NR, Nunez, C. (2004) No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract 10: 227-232.
25. Moore, NC, Shukla, P. (1997) Risperidone overdose. Am J Psychiatry 154: 289-290.
26. Moss, AJ (1999) The QT interval and torsades de pointes. Drug Saf 21 (Suppl. 1). 5-10.
27. Parsons, M., Buckley, NA (1997) Overdose of antipsychotic drugs: practical management guidelines. CNS Drugs 7: 427-441.
28. Pfizer (2007) Geodon (ziprasidone HCl) capsules, Geodon (ziprasidone mesylate) for injection. http://www.pfizer.com/files/products/uspi-geodon.pdf (accessed 18.01.08).
29. Roberts, DJ (1999) Assessing the cardiac safety of ebastine. Prologue. Drug Saf 21 (Suppl. 1). 1-3.
30. Rodriguez, I., Kilborn, MJ, Liu, XK, Pezzullo, JC, Woosley, RL (2001) Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285: 1322-1326.
31. Sadeque, AJ, Fisher, MB, Korzekwa, KR, Gonzalez, FJ, Rettie, AE (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 283: 698-703.
32. Scheen, AJ (1996) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30: 359-371.
33. Scheen, AJ (2005) Drug interactions of clinical importance with anti-hyperglycaemic agents: an update. Drug Saf 28: 601-631.
34. Simpson, GM, Weiden, P., Pigott, T., Murray, S., Siu, CO, Romano, SJ (2005) Six- month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 162: 1535-1538.
35. Small, JG, Hirsch, SR, Arvanitis, LA, Miller, BG, Link, CG (1997) Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54: 549-557.
36. Taylor, D. (2003) Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 17: 423-430.
37. Zareba, W., Lin, DA (2003) Antipsychotic drugs and QT interval prolongation. Psychiatr Q 74: 291-306.